Rima Rachid, MD
Director of Allergen Immunotherapy, Allergy and Asthma Program; Co-Director, Food Allergy Program; Immunologist, Division of Immunology
Associate Professor of Pediatrics, Harvard Medical School
Image
Rima Rachid, MD
Director of Allergen Immunotherapy, Allergy and Asthma Program; Co-Director, Food Allergy Program; Immunologist, Division of Immunology
Associate Professor of Pediatrics, Harvard Medical School
Medical Services
Languages
Arabic
English
Education
Medical School
American University of Beirut
1995
Beirut
Lebanon
Internship
American University of Beirut
1996
Beirut
Lebanon
Residency
American University of Beirut
1998
Beirut
Lebanon
Fellowship
Boston Children's Hospital
2002
Boston
MA
Residency
Boston Children's Hospital
2004
Boston
MA
Certifications
American Board of Allergy & Immunology (General)
Publications
RELMß sets the threshold for microbiome-dependent oral tolerance. View Abstract
Towards a common approach for managing food allergy and serious allergic reactions (anaphylaxis) at school. GA2LEN and EFA consensus statement. View Abstract
10 practical priorities to prevent and manage serious allergic reactions: GA2LEN ANACare and EFA Anaphylaxis Manifesto. View Abstract
The use and implementation of omalizumab as food allergy treatment: Consensus-based guidance and Work Group Report of the Adverse Reactions to Foods Committee of the American Academy of Allergy, Asthma & Immunology. View Abstract
Age-specific Metabolomic profiles in children with food allergy. View Abstract
The use of adjunctive therapies during oral immunotherapy: A focus on biologics. View Abstract
High-resolution epitope mapping by AllerScan reveals relationships between IgE and IgG repertoires during peanut oral immunotherapy. View Abstract
Biologics and Novel Therapies for Food Allergy. View Abstract
Continuous and Daily Oral Immunotherapy for Peanut Allergy: Results from a 2-Year Open-Label Follow-On Study. View Abstract
The microbial origins of food allergy. View Abstract
Regulatory T Cell-Derived TGF-ß1 Controls Multiple Checkpoints Governing Allergy and Autoimmunity. View Abstract
Regulatory T Cell-Derived TGF-ß1 Controls Multiple Checkpoints Governing Allergy and Autoimmunity. View Abstract
Practical Guidance for the Evaluation and Management of Drug Hypersensitivity: Specific Drugs. View Abstract
[Erratum to "Unusual bilateral eyelid and orbital involvement in Rosai-Dorfman disease (a comprehensive literature review and case report)" [J. Fr. Ophtalmol. 39 (2016) e221-e225]]. View Abstract
Novel Therapies for Treatment of Food Allergy. View Abstract
Peanut Oral Immunotherapy: Is It Safer in Preschoolers than in Older Age Groups? View Abstract
Untargeted metabolomic profiling identifies disease-specific signatures in food allergy and asthma. View Abstract
Author Correction: Microbiota therapy acts via a regulatory T cell MyD88/ROR?t pathway to suppress food allergy. View Abstract
Microbiota therapy acts via a regulatory T cell MyD88/ROR?t pathway to suppress food allergy. View Abstract
Reply. View Abstract
The emerging biologic therapies on food allergy. View Abstract
AR101 Oral Immunotherapy for Peanut Allergy. View Abstract
Immunoglobulin E blockade during food allergen ingestion enhances the induction of inhibitory immunoglobulin G antibodies. View Abstract
Acquired Cold-Induced Urticaria in Pediatric Patients: A 22-Year Experience in a Tertiary Care Center (1996-2017). View Abstract
Long-Term Outcome of Peanut Oral Immunotherapy Facilitated Initially by Omalizumab. View Abstract
Defective TLR9-driven STAT3 activation in B cells of patients with CVID. View Abstract
A twenty-two-year experience with Hymenoptera venom immunotherapy in a US pediatric tertiary care center 1996-2018. View Abstract
Oral immunotherapy with omalizumab reverses the Th2 cell-like programme of regulatory T cells and restores their function. View Abstract
Food Allergy: What's on the Menu in 2018? View Abstract
Systemic Reactions in Pediatric Patients Receiving Standardized Allergen Subcutaneous Immunotherapy with and without Seasonal Dose Adjustment. View Abstract
Current Status and Unanswered Questions for Food Allergy Treatments. View Abstract
Efficacy and Safety of AR101 in Oral Immunotherapy for Peanut Allergy: Results of ARC001, a Randomized, Double-Blind, Placebo-Controlled Phase 2 Clinical Trial. View Abstract
Construction and validation of a novel disease-specific quality-of-life instrument for patients with primary antibody deficiency disease (PADQOL-16). View Abstract
The role of the gut microbiota in food allergy. View Abstract
Omalizumab facilitates rapid oral desensitization for peanut allergy. View Abstract
The Heterogeneity of Oral Immunotherapy Clinical Trials: Implications and Future Directions. View Abstract
Oral immunotherapy and anti-IgE antibody treatment for food allergy. View Abstract
TNF receptor superfamily member 13b (TNFRSF13B) hemizygosity reveals transmembrane activator and CAML interactor haploinsufficiency at later stages of B-cell development. View Abstract
Regulatory T cell reprogramming toward a Th2-cell-like lineage impairs oral tolerance and promotes food allergy. View Abstract
Oral immunotherapy induces IgG antibodies that act through Fc?RIIb to suppress IgE-mediated hypersensitivity. View Abstract
A pilot study of omalizumab to facilitate rapid oral desensitization in high-risk peanut-allergic patients. View Abstract
CVID-associated TACI mutations affect autoreactive B cell selection and activation. View Abstract
[Use of bevacizumab in the treatment of complicated proliferative diabetic retinopathy]. View Abstract
Administration of intravenous immunoglobulin to a patient with hypogammaglobulinemia and anti-IgA antibodies. View Abstract
Immunological mechanisms for desensitization and tolerance in food allergy. View Abstract
Reply. View Abstract
Intraoperative anaphylaxis induced by the gelatin component of thrombin-soaked gelfoam in a pediatric patient. View Abstract
The role of anti-IgA antibodies in causing adverse reactions to gamma globulin infusion in immunodeficient patients: a comprehensive review of the literature. View Abstract
Reply. View Abstract
Reply. View Abstract
Association of anti-IgA antibodies with adverse reactions to ?-globulin infusion. View Abstract
Hypersensitivity to systemic corticosteroids: an infrequent but potentially life-threatening condition. View Abstract
Reexamining the role of TACI coding variants in common variable immunodeficiency and selective IgA deficiency. View Abstract
TACI mutation in common variable immunodeficiency and IgA deficiency. View Abstract
TACI is mutant in common variable immunodeficiency and IgA deficiency. View Abstract
Mechanism of recruitment of WASP to the immunological synapse and of its activation following TCR ligation. Mol Cell View Abstract
Treatment-resistant infantile Evans syndrome. View Abstract
Consequences of alpha-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid receptor blockade during status epilepticus in the developing brain. View Abstract
p53-dependent ceramide response to genotoxic stress. View Abstract